GGrantIndex
← Search

Cancer Biology Program

$63,478P30FY2021CANIH

University Of Nebraska Medical Center, Omaha NE

Investigators

Linked publications, trials & patents

Paper 39684445Paper 39678719Paper 39605468Paper 39580490Paper 39573886Paper 39456534Paper 39450301Paper 39436320Paper 39420209Paper 39386613Paper 39386448Paper 39384153Paper 39339419Paper 39224072Paper 39219576Paper 39151112Paper 39141488Paper 39130636Paper 39125017Paper 39110778Paper 39107463Paper 39080401Paper 39013847Paper 38974465Paper 38969056Paper 38946943Paper 38900505Paper 38853862Paper 38847506Paper 38775157Paper 38770637Paper 38733583Paper 38712184Paper 38704607Paper 38687198Paper 38683788Paper 38672426Paper 38617282Paper 38603627Paper 38547055Paper 38542184Paper 38514303Paper 38482976Paper 38445903Paper 38437585Paper 38429478Trial NCT03226418Trial NCT03073785Trial NCT02874404Trial NCT02833701Trial NCT02654119Trial NCT02561273Trial NCT02553447Trial NCT02168270Trial NCT01959672Trial NCT01825603Trial NCT01750073Trial NCT01555632Trial NCT01431209Trial NCT01336933Trial NCT01336920Trial NCT01307956Trial NCT01106898Trial NCT01093183Trial NCT01068327Trial NCT01044745Trial NCT01035463Trial NCT00959244Trial NCT00856037Trial NCT00816413Trial NCT00736450Trial NCT00679029Trial NCT00666731Trial NCT00665457Trial NCT00625690Trial NCT00617799Trial NCT00611351Trial NCT00607828Trial NCT00602797Trial NCT00577798Trial NCT00569543Trial NCT00503880Trial NCT00499083Trial NCT00496756Trial NCT00486356Trial NCT00483561Trial NCT00483366Trial NCT00482807Trial NCT00089024Trial NCT00082641Trial NCT00007865Trial NCT00007852Trial NCT00006478Trial NCT00004874Trial NCT00004198Trial NCT00004197Trial NCT00004192Trial NCT00004112Patent 7166704Patent 6680196

Abstract

Project Summary/Abstract: Cancer Biology Program (CBP) The overall goal of research in the Cancer Biology Program (CBP), previously the Molecular and Biochemical Etiology Program, is to understand mechanisms that underlie cancer initiation and progression that could lead to new biomarkers and interventional strategies to positively impact cancer diagnosis, prevention, and therapeutic strategies across cancers prevalent in the BCC catchment area. To clearly delineate our mission and themes, we strategically reorganized the program to focus on basic cancer mechanisms, with translational efforts pursued in collaboration with the Targets, Modulators, and Delivery (TMDP) and GI Cancer (GICP) programs. To this end, we retained 14 prior members and added 24 new investigators with a basic cancer biology focus. The major goals of the CBP are to define the molecular mechanisms that maintain genome stability and their alterations in cancer, dissect intracellular signaling mechanisms and tumor cell-microenvironment interactions, and elucidate and harness metabolic and other mechanisms that lead to host systemic organ dysfunction and contribute to cancer patient morbidity and mortality. The 38 CBP members come from eight departments across the University with multidisciplinary interests in DNA damage/repair processes, signaling mechanisms, metabolomics, redox biology, and cell- and animal-based cancer models. The research interests of program members are organized around three Themes. Theme 1. Genome Instability and Cancer. Members focus on studies of genome replication, DNA damage responses and repair, and identification of new genomic alterations that drive hereditary or sporadic cancer. Theme 2. Signaling Mechanisms in Cancer. Members focus on elucidating intra- and inter-cellular signaling mechanisms that drive tumorigenesis and metastasis. Theme 3. Metabolic Alterations and Systemic Dysfunction in Cancer. Members focus on cancer cell metabolism and redox biology, and the impact of tumor burden on organ systems, with a particular focus on cancer cachexia and fatigue. There is extensive cross-talk between Themes, and basic mechanisms and pathways elucidated under CBP provide a rich basis for inter-programmatic collaborations with TMDP and GICP towards further translation into potential target validation and inhibitor design and translational studies. The Co-Leaders leverage their complementary expertise to enhance inter- and intra-programmatic collaborations through the development and employment of new and existing shared resources, evaluation and funding of pilot projects supporting the CBP mission, involvement in faculty recruitment, and organization of regular programmatic meetings. These activities have led to a strong collaborative group as demonstrated by impactful inter- and intra-programmatic, cancer- focused publications and grants, and an increased focus on basic biology with the potential for clinical translation. Cancer-relevant peer-reviewed CBP funding is $6.87M (direct), of which $1.9M is from the NCI. During the previous funding period, CBP members reported 304 cancer-relevant publications, with 43% intra-programmatic, 45% inter-programmatic, 28% both intra- and inter-programmatic, and 38% inter-institutional publications.

View original record on NIH RePORTER →